Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach

Investigative Ophthalmology and Visual Science

Volumn 58, Issue 7, 2017, Pages 3240-3248

  Bogunović, Hrvoje ^a   Waldstein, Sebastian M ^a   Schlegl, Thomas ^a   Langs, Georg ^a   Sadeghipour, Amir ^a   Liu, Xuhui ^a,b   Gerendas, Bianca S ^a   Osborne, Aaron ^c   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c GENENTECH INC   (United States)

Author keywords

Anti VEGF therapy; Choroidal neovascularization; Image analysis; Machine learning; Optical coherence tomography

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

A SCAN; ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ALGORITHM; ANKLE BRACHIAL INDEX; ARTICLE; B SCAN; BEST CORRECTED VISUAL ACUITY; CONTROLLED STUDY; CONVOLUTIONAL NEURAL NETWORK; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMAGE SEGMENTATION; INTRAOCULAR PRESSURE; MACHINE LEARNING; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL; PHOTORECEPTOR; PILOT STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOM FOREST; RANDOMIZED CONTROLLED TRIAL; RETINA BLOOD VESSEL; RETINA FOVEA; RETINAL INNER NUCLEAR LAYER; RETINAL INNER PLEXIFORM LAYER; RETINAL NERVE FIBER LAYER THICKNESS; RETINAL OUTER NUCLEAR LAYER; RETINAL PIGMENT EPITHELIUM; RETINAL THICKNESS; SENSITIVITY AND SPECIFICITY; SOMATOSENSORY CORTEX; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; THREE-DIMENSIONAL IMAGING; VISUAL ACUITY; VISUAL FIELD; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; MACULAR DEGENERATION; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MACHINE LEARNING; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RANIBIZUMAB; ROC CURVE; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85024379161     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-21053     Document Type: Article

References (23)

1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606–2617.
2. Maguire MG, Martin DF, Ying G-S, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–1761.
3. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209–213.
4. Sloan FA, Hanrahan BW. The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol. 2014;132:456–463.
5. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046–1056.
6. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117:2134–2140.
7. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1–24.
8. Chakravarthy U, Goldenberg D, Young G, et al. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731–1736.
9. Montuoro A, Wu J, Waldstein S, et al. Motion artefact correction in retinal optical coherence tomography using local symmetry. In: Golland P, Hata N, Barillot C, Hornegger J, Hower R, eds. Medical Image Computing and Computer-Assisted Intervention LNCS Vol. 8674. Cham, Switzerland: Springer; 2014:130–137.
10. Garvin MK, Abràmoff MD, Wu X, Russell SR, Burns TL, Sonka M. Automated 3-D intraretinal layer segmentation of macular spectral-domain optical coherence tomography images. IEEE Trans Med Imaging. 2009;28:1436–1447.
11. Li K, Wu X, Chen DZ, Sonka M. Optimal surface segmentation in volumetric images: a graph-theoretic approach. IEEE Trans Pattern Anal Mach Intell. 2006;28:119–134.
12. Schlegl T, Waldstein SM, Vogl W-D, Schmidt-Erfurth U, Langs G. Predicting semantic descriptions from medical images with convolutional neural networks. In: Ourselin S, Alexander DC, Westin CF, Cardoso MJ, eds. Information Processing in Medical Imaging. LNCS Vol. 9123. Cham, Switzerland: Springer; 2015:437–448.
13. Breiman L. Random forests. Mach Learn. 2001;45:5–32.
14. Vogl W-D, Waldstein S, Gerendas B, et al. Spatio-temporal signatures to predict retinal disease recurrence. In: Ourselin S, Alexander DC, Westin CF, Cardoso MJ, eds. Information Processing in Medical Imaging. LNCS Vol. 9123. Cham, Switzerland: Springer; 2015:152–163.
15. Bogunović H, Abramoff MD, Zhang L, Sonka M. Prediction of treatment response from retinal oct in patients with exudative age-related macular degeneration. In: Chen X, Garvin MK, Liu JJ, eds. IProceedings of the Ophthalmic Medical Image Analysis First International Workshop, OMIA 2014. Boston, MA, September 14, 2014;129–136.
16. de Sisternes L, Simon N, Tibshirani R, Leng T, Rubin DL. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Invest Ophthalmol Vis Sci. 2014;55:7093–7103.
17. Ying GS, Maguire MG, Daniel E, et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015;122:2523–2531.
18. Chakravarthy U, Harding SP, Rogers CA, et al. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN). Health Technol Assess (Rockv). 2015;19:1–298.
19. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300–2309.
20. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–1183.
21. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study: a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013;91:540–546.
22. Holz FG, Bandello F, Gillies M, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97:1161–1167.
23. Jaffe GJ, Kaiser PK, Thompson D, et al. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123:1856–1864.